Definiens and Ultivue Announce a Collaboration to Co-Develop Joint Offerings in Multiplexed Immunofluorescence (IF) and AI Enabled Digital Image Analysis

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Ultivue, a developer of tissue biomarker identification and
quantification assays for translational and pathology research labs, and
Definiens, a pioneer in artificial intelligence (AI) based image
analysis, today announced a collaboration to expand Definiens
standardized IO-Panel capabilities to IF. The collaboration will provide
a standardized and scalable solution to enable access to IF multiplex
immunohistochemistry (IHC) assays. The joint offering will
comprehensively address clinical research and translational medicine
market needs by combining Ultivue’s UltiMapper™ I/O kits and services
with Definiens’ first in class digital image analysis, powered by Tissue
Phenomics®, supported by leading machine learning technologies.

“We see great opportunities in expanding the existing IO-Panel solutions
to IF. The collaboration with Ultivue will enable us to provide IO
profiles from a single tissue section – and we can use additional serial
sections to investigate other relevant biomarkers,” said Thomas Heydler,
CEO, Definiens. “Analysis of spatial relationships at cellular
resolution with IF multiplexing will also add biological depth and
context. Ultivue’s ability to provide kits paired with Definiens’
web-based analytics infrastructure will put the power of standardized IO
profiling at the fingertips of researchers across the globe.”

The joint offering will initially be based on the UltiMapper I/O PD-L1
and PD-1 kit panels and will further expand to a co-developed 8-plex IF
immuno-oncology panel. “Ultivue is excited to announce this first
collaboration with Definiens that leverages the core competences and
offerings of our respective organizations to deliver standardized
multiplex staining, imaging and image analysis on FFPE tissue samples,”
said Michael Natan, CEO, Ultivue. “Scientists taking advantage of the
joint offering will be able to access comprehensive analyses of tumor
microenvironment and immune cell phenotypes from their precious
samples,” Natan added.

Ultivue and Definiens scientific teams will be present at their
respective company booths #2048 and #2350 at the annual meeting of the
American Association of Cancer Research (AACR), from March 29 through
April 3, 2019 in Atlanta, Georgia.

About Ultivue
By developing novel, proprietary reagents used
both for biomarker discovery (higher content, low throughput) and
translational use (lower content, high throughput), Ultivue is
connecting the insights gained from research directly into the pathology
lab. Ultivue’s UltiMapper™ multiplexed assays applied to tissue biopsy
samples enable simultaneous quantitation of multiple biomarkers with
sub-cellular spatial resolution and fit completely within traditional
IHC workflows. Translational and clinical researchers leverage
UltiMapper™ assays to elucidate complex biology and demonstrate their
clinical utility as precision medicine research tools. Ultivue is
expanding its UltiMapper™ assay product portfolio and menu of contract
research services to provide a comprehensive set of personalized
medicine solutions for research in oncology research and other
therapeutic areas.

Ultivue is based in Cambridge, MA. For more information, visit www.ultivue.com.
For
Research Use Only. Not for use in diagnostic procedures.

About Definiens

Founded in 1994 by Nobel Laureate Dr. Gerd Binning, Definiens is now a
leading tissue image analysis and data mining provider in the life
science sector. As a pioneer in Artificial Intelligence (AI) based image
analysis, Definiens leverages the rich content and context in the tumor
microenvironment of the patient’s tissue to find biomarker signatures
for robust patient stratification. This helps pave the way for
personalized immunotherapy.

Definiens is a member of the AstraZeneca group and a trusted global
partner for researchers in biotechnology. Additional clients include
renowned biopharmaceuticals and prestigious academics, who have
collectively published over 1,000 scientific papers using Definiens’
products and services.

Please visit www.definiens.com
and follow us on social media for the latest developments.

Definiens IO-Panel is for research use only.

Contacts

Ultivue Contact:
Louis Levy
+1-617-945-2662
[email protected]

Definiens Contact:
Contact and inquiries: [email protected]